We suggest, that partial agonists of α2A/B-adrenoreceptors with a very weak intrinsic activity seem to offer a potential for a good and effective treatment of obesity, with a lower risk of side effects associated with the cardiovascular system. The gene discussed is IGKV2D-29; the disease is obesity due to melanocortin 4 receptor deficiency.